News

Sept 06, 2023

News

Proteros biostructures and Orion Pharma agree on a long-term multi-target collaboration including the assembly of a joint novel and unique HTS small-molecule screening library with full chemistry support of Enamine

READ MORE

Jan 09, 2023

News

Proteros receives minority investment from private equity firm Inflexion

READ MORE

Oct 25, 2022

News

Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases

READ MORE

May 16, 2022

News

Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca

READ MORE

December 13, 2021

News

Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under Covid-19 Discovery Research and License Agreement

READ MORE

Jun 02 2021

News

Proteros Enters into Oncology Collaboration and License Agreement with AstraZeneca

READ MORE

Apr 01 2021

News

Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement

READ MORE

Oct 01 2020

News

Proteros Biostructures and X-Chem to Offer Comprehensive Joint Target-to-Lead Drug Discovery Services

READ MORE

Sept 01 2020

News

Proteros launches new cryo-EM facility to speed drug discovery

READ MORE